Connect with us


GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) Halts Its Decline



In the last trading session, the stock price of GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) gained 0.32% to close the day at $111.16. GW Pharmaceuticals is a biopharmaceutical company that concentrates its efforts on discovering, developing and commercializing innovative therapeutics from its proprietary Hemp product platform in an extensive range of disease areas.

The highlights

As per a forecast report by Arcview Market Research, the development in the approved cannabis market will re-accelerate at the start of 2018, as adult use sales are anticipated to ramp up in Canada, Massachusetts and California along with medicinal sales in Florida. The market is anticipated to grow at a CAGR of 27% to $22.6 billion in 2021 from the $6.7 billion market value in the last year.

Polls demonstrate that 80% of Americans permit of legal access to medical cannabis while 60% approve of adult use legalization. That level of arrangement is rare on any policy concern and it’s allowing elected executives across the political spectrum to begin to move past the stigma previously linked with this issue. Hence, the companies in focus will be GW Pharmaceuticals, CANNABIS WHEATON I COM NPV (OTCMKTS:KWFLF), Axim Biotechnologies Inc (OTCMKTS:AXIM), Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) and 22nd Century Group Inc (NYSEAMERICAN:XXII).

Forbes reported that retail sales in the United States from 20 jurisdictions came at $6.5 billion, however as per Greenwave Advisors, that figure is estimated to grow to $30 billion by 2021. In attempt to meet the demand for consumers, the makers and growers of infused offerings have to scale up their businesses. More square footage, more automation and the ability to accomplish this fast growth are separating the pop and mom shops from corporate cannabis.

GW Pharmaceuticals is advancing an orphan drug plan in the segment of childhood-onset epilepsy with a concentration on Epidiolex®, which is in Phase III clinical advancement for the cure of Dravet syndrome, Tuberous Sclerosis Complex, Infantile Spasms and Lennox-Gastaut syndrome.

*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.